Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines - PubMed (original) (raw)
. 2006 Mar 1;176(5):2722-9.
doi: 10.4049/jimmunol.176.5.2722.
Nathalie Chaput, Noël Schartz, Stéphan Roux, Sophie Novault, Cédric Ménard, François Ghiringhelli, Magali Terme, Antoine F Carpentier, Guillaume Darrasse-Jèze, François Lemonnier, Laurence Zitvogel
Affiliations
- PMID: 16493027
- DOI: 10.4049/jimmunol.176.5.2722
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines
Julien Taieb et al. J Immunol. 2006.
Erratum in
- J Immunol. 2006 Aug 1;177(3):2024. Darrasse-Jèse, Guillaume [corrected to Darrasse-Jèze, Guillaume]
Abstract
Dendritic cell-derived exosomes (DEX) are nanomeric vesicles harboring MHC/peptide complexes capable of promoting primary T cell responses and tumor rejection in the presence of adjuvants. In this study, we show that, in the absence of adjuvants, DEX mediate potent Ag-dependent antitumor effects against preestablished tumors in mice pretreated with immunopotentiating dosing of cyclophosphamide. Cyclophosphamide could 1) abolish the suppressive function of CD4+CD25+Foxp3+ regulatory T cells, 2) markedly enhance the magnitude of secondary but not primary CTL responses induced by DEX vaccines, 3) synergize with DEX in therapy but not prophylaxis tumor models. Therefore, therapeutic vaccines such as DEX aimed at boosting tumor-primed effector T cells could benefit procedures that minimize the effects of CD4+CD25+ regulatory T cells.
Similar articles
- Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
Chaput N, Schartz NE, André F, Taïeb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel L. Chaput N, et al. J Immunol. 2004 Feb 15;172(4):2137-46. doi: 10.4049/jimmunol.172.4.2137. J Immunol. 2004. PMID: 14764679 - CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM. Hanson HL, et al. J Immunol. 2004 Apr 1;172(7):4215-24. doi: 10.4049/jimmunol.172.7.4215. J Immunol. 2004. PMID: 15034034 - The potential of exosomes in immunotherapy.
Chaput N, Taïeb J, André F, Zitvogel L. Chaput N, et al. Expert Opin Biol Ther. 2005 Jun;5(6):737-47. doi: 10.1517/14712598.5.6.737. Expert Opin Biol Ther. 2005. PMID: 15952905 Review. - Dendritic cell-derived exosomes as cell-free peptide-based vaccines.
Taïeb J, Chaput N, Zitvogel L. Taïeb J, et al. Crit Rev Immunol. 2005;25(3):215-23. doi: 10.1615/critrevimmunol.v25.i3.30. Crit Rev Immunol. 2005. PMID: 16048436 Review.
Cited by
- Portrait of an autologous cancer vaccine: Then and now.
Berd D. Berd D. Hum Vaccin Immunother. 2023 Dec 31;19(1):2172925. doi: 10.1080/21645515.2023.2172925. Epub 2023 Feb 8. Hum Vaccin Immunother. 2023. PMID: 36755486 Free PMC article. - Neoantigen-based cancer vaccination using chimeric RNA-loaded dendritic cell-derived extracellular vesicles.
Xiong X, Ke X, Wang L, Lin Y, Wang S, Yao Z, Li K, Luo Y, Liu F, Pan Y, Yeung SJ, Helfrich W, Zhang H. Xiong X, et al. J Extracell Vesicles. 2022 Aug;11(8):e12243. doi: 10.1002/jev2.12243. J Extracell Vesicles. 2022. PMID: 35927827 Free PMC article. - Upcoming immunotherapeutic combinations for B-cell lymphoma.
Greve P, Meyer-Wentrup FAG, Peperzak V, Boes M. Greve P, et al. Immunother Adv. 2021 Feb 9;1(1):ltab001. doi: 10.1093/immadv/ltab001. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919738 Free PMC article. Review. - Exosomes reveal the dual nature of radiotherapy in tumor immunology.
Hu X, Qiu Y, Zeng X, Wang H. Hu X, et al. Cancer Sci. 2022 Apr;113(4):1105-1112. doi: 10.1111/cas.15314. Epub 2022 Mar 7. Cancer Sci. 2022. PMID: 35218675 Free PMC article. Review. - Role of Exosomes for Delivery of Chemotherapeutic Drugs.
Gebeyehu A, Kommineni N, Meckes DG Jr, Sachdeva MS. Gebeyehu A, et al. Crit Rev Ther Drug Carrier Syst. 2021;38(5):53-97. doi: 10.1615/CritRevTherDrugCarrierSyst.2021036301. Crit Rev Ther Drug Carrier Syst. 2021. PMID: 34375513 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials